NASDAQ:JAZZ Jazz Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Jazz Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. $158.58 +2.57 (+1.65%) (As of 07/1/2022 12:00 AM ET) Add Compare Share Today's Range$153.96▼$159.2850-Day Range$141.59▼$166.1452-Week Range$117.64▼$186.22Volume387,944 shsAverage Volume589,968 shsMarket Capitalization$9.90 billionP/E RatioN/ADividend YieldN/APrice Target$204.14 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Jazz Pharmaceuticals Stock Forecast (MarketRank)Analyst RatingModerate Buy2.82 Rating ScoreUpside/Downside28.8% Upside$204.14 Price TargetShort InterestHealthy5.06% of Float Sold ShortDividend StrengthN/ASustainability-1.96Upright™ Environmental ScoreNews Sentiment0.06Based on 14 Articles This WeekInsider TradingSelling Shares$7.42 M Sold Last QuarterProj. Earnings Growth8.15%From $14.73 to $15.93 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.29 out of 5 starsMedical Sector188th out of 1,429 stocksPharmaceutical Preparations Industry71st out of 682 stocks 3.4 Analyst's Opinion Consensus RatingJazz Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $204.14, Jazz Pharmaceuticals has a forecasted upside of 28.8% from its current price of $158.54.Amount of Analyst CoverageJazz Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.06% of the float of Jazz Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverJazz Pharmaceuticals has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Jazz Pharmaceuticals has recently decreased by 13.80%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldJazz Pharmaceuticals does not currently pay a dividend.Dividend GrowthJazz Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreJazz Pharmaceuticals has received a 54.43% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Leukemia medication", "Lung cancer medication", and "Anticoagulant medication (B01)" products. See details.Environmental SustainabilityThe Environmental Impact score for Jazz Pharmaceuticals is -1.96. Previous Next 2.3 News and Social Media Coverage News SentimentJazz Pharmaceuticals has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Jazz Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 7 people have searched for JAZZ on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.MarketBeat Follows14 people have added Jazz Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Jazz Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,415,201.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of Jazz Pharmaceuticals is held by insiders.Percentage Held by Institutions93.23% of the stock of Jazz Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Jazz Pharmaceuticals are expected to grow by 8.15% in the coming year, from $14.73 to $15.93 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jazz Pharmaceuticals is -21.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Jazz Pharmaceuticals is -21.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioJazz Pharmaceuticals has a PEG Ratio of 1.27. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioJazz Pharmaceuticals has a P/B Ratio of 2.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive JAZZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address About Jazz Pharmaceuticals (NASDAQ:JAZZ)Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.Read More JAZZ Stock News HeadlinesJuly 1, 2022 | finance.yahoo.comWhat Bear Market? These 2 Stocks Are Killing It.July 1, 2022 | americanbankingnews.comJazz Pharmaceuticals (NASDAQ:JAZZ) Upgraded to "Buy" at StockNews.comJune 30, 2022 | americanbankingnews.comJazz Pharmaceuticals plc (NASDAQ:JAZZ) SVP Samantha Pearce Sells 8,508 Shares of StockJune 29, 2022 | finance.yahoo.comJAZZ's Late-Stage Multiple Sclerosis Study on Nabiximols FailsJune 29, 2022 | finance.yahoo.comIBD 50 Stocks To Watch: This Pharma Stock Rides Health Care WaveJune 28, 2022 | finance.yahoo.comJazz Pharma's Cannabidiol Mixture Spray Misses Primary Goal In Multiple Sclerosis SpasticityJune 28, 2022 | benzinga.comJazz Pharmaceuticals' Late-Stage Multiple Sclerosis Study Misses Primary EndpointJune 28, 2022 | finance.yahoo.comJazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis SpasticityJune 28, 2022 | finance.yahoo.comStock Market Plunge: 5 Unstoppable Stocks Begging to Be BoughtJune 26, 2022 | americanbankingnews.comAnalysts Set Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Target Price at $204.14June 23, 2022 | finance.yahoo.comAre Options Traders Betting on a Big Move in Jazz Pharmaceuticals (JAZZ) Stock?June 16, 2022 | seekingalpha.comAvadel: Further Delay, But Some Light At The End Of The TunnelJune 15, 2022 | seekingalpha.comJazz to start clinical trial for tumor candidate after FDA nodSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:JAZZ CUSIPG5087110 CIK1232524 Webwww.jazzpharma.com Phone(531) 634-7800Fax353-1634-7850Employees3,200Year Founded2003Company Calendar Last Earnings5/04/2022Today7/01/2022Next Earnings (Estimated)8/02/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$204.14 High Stock Price Forecast$225.00 Low Stock Price Forecast$174.00 Forecasted Upside/Downside+28.7%Consensus RatingModerate Buy Rating Score (0-4)2.81818181818182 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($7.510010) Trailing P/E RatioN/A Forward P/E Ratio10.77 P/E Growth1.27Net Income$-329.67 million Net Margins-13.63% Pretax Margin-7.34% Return on Equity22.45% Return on Assets7.06% Debt Debt-to-Equity Ratio1.66 Current Ratio3.39 Quick Ratio2.06 Sales & Book Value Annual Sales$3.09 billion Price / Sales3.20 Cash Flow$23.70 per share Price / Cash Flow6.69 Book Value$64.51 per share Price / Book2.46Miscellaneous Outstanding Shares62,443,000Free Float59,696,000Market Cap$9.90 billion OptionableOptionable Beta0.80 Social Links Jazz Pharmaceuticals Frequently Asked Questions Should I buy or sell Jazz Pharmaceuticals stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Jazz Pharmaceuticals stock. View analyst ratings for Jazz Pharmaceuticals or view top-rated stocks. What is Jazz Pharmaceuticals' stock price forecast for 2022? 11 brokerages have issued 12-month target prices for Jazz Pharmaceuticals' shares. Their JAZZ stock forecasts range from $174.00 to $225.00. On average, they predict Jazz Pharmaceuticals' share price to reach $204.14 in the next year. This suggests a possible upside of 28.7% from the stock's current price. View analysts' price targets for Jazz Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has Jazz Pharmaceuticals' stock price performed in 2022? Jazz Pharmaceuticals' stock was trading at $127.40 at the beginning of the year. Since then, JAZZ shares have increased by 24.5% and is now trading at $158.58. View the best growth stocks for 2022 here. When is Jazz Pharmaceuticals' next earnings date? Jazz Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022. View our earnings forecast for Jazz Pharmaceuticals. How were Jazz Pharmaceuticals' earnings last quarter? Jazz Pharmaceuticals plc (NASDAQ:JAZZ) posted its quarterly earnings results on Wednesday, May, 4th. The specialty pharmaceutical company reported $3.13 earnings per share for the quarter, topping the consensus estimate of $3.00 by $0.13. The specialty pharmaceutical company earned $813.72 million during the quarter, compared to analyst estimates of $853.73 million. Jazz Pharmaceuticals had a negative net margin of 13.63% and a positive trailing twelve-month return on equity of 22.45%. The firm's quarterly revenue was up 33.9% on a year-over-year basis. During the same period in the prior year, the firm posted $3.42 EPS. View Jazz Pharmaceuticals' earnings history. What guidance has Jazz Pharmaceuticals issued on next quarter's earnings? Jazz Pharmaceuticals issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $3.50 billion-$3.70 billion, compared to the consensus revenue estimate of $3.58 billion. Who are Jazz Pharmaceuticals' key executives? Jazz Pharmaceuticals' management team includes the following people: Mr. Bruce C. Cozadd, Co-Founder, Chairman & CEO (Age 58, Pay $2.27M) (LinkedIn Profile)Mr. Daniel N. Swisher Jr., Pres (Age 59, Pay $1.27M)Ms. Renee D. Gala, Exec. VP & CFO (Age 50, Pay $1.03M)Mr. Christopher John Tovey BSc, Exec. VP, COO and MD of Europe & International (Age 57, Pay $880.61k)Dr. Robert Iannone M.D., Exec. VP and Global Head of R&D (Age 55, Pay $983.25k)Ms. Patricia Carr, Sr. VP & Chief Accounting Officer (Age 51) (LinkedIn Profile)Dr. Finbar Larkin Ph.D., Sr. VP of Technical Operations (Age 64)Ms. Andrea N. Flynn Ph.D., VP & Head of Investor RelationsMs. Neena M. Patil J.D., Chief Legal Officer and Sr. VP of Legal & Corp. Affairs (Age 47) (LinkedIn Profile)Dr. George Christopher Eliades Ph.D., Sr. VP of Corp. Devel. & Chief Transformation Officer (Age 52) What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO? 60 employees have rated Jazz Pharmaceuticals CEO Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among Jazz Pharmaceuticals' employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Jazz Pharmaceuticals' key competitors? Some companies that are related to Jazz Pharmaceuticals include Johnson & Johnson (JNJ), Eli Lilly and (LLY), Pfizer (PFE), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Perrigo (PRGO), Corcept Therapeutics (CORT), Pacira BioSciences (PCRX), Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR) and Omeros (OMER). View all of JAZZ's competitors. What other stocks do shareholders of Jazz Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib). What is Jazz Pharmaceuticals' stock symbol? Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ." How do I buy shares of Jazz Pharmaceuticals? Shares of JAZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Jazz Pharmaceuticals' stock price today? One share of JAZZ stock can currently be purchased for approximately $158.58. How much money does Jazz Pharmaceuticals make? Jazz Pharmaceuticals (NASDAQ:JAZZ) has a market capitalization of $9.90 billion and generates $3.09 billion in revenue each year. The specialty pharmaceutical company earns $-329.67 million in net income (profit) each year or ($7.510010) on an earnings per share basis. How many employees does Jazz Pharmaceuticals have? Jazz Pharmaceuticals employs 3,200 workers across the globe. Does Jazz Pharmaceuticals have any subsidiaries? The following companies are subsidiares of Jazz Pharmaceuticals: Cavion.Read More When was Jazz Pharmaceuticals founded? Jazz Pharmaceuticals was founded in 2003. How can I contact Jazz Pharmaceuticals? Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The official website for Jazz Pharmaceuticals is www.jazzpharma.com. The specialty pharmaceutical company can be reached via phone at (531) 634-7800, via email at [email protected], or via fax at 353-1634-7850. This page (NASDAQ:JAZZ) was last updated on 7/1/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
